Abstract: Anti-SIRP? monoclonal antibodies (anti-SIRP-alpha mAbs), including multi-specific SIRP? antibodies, are provided with distinct functional profiles as are related compositions and methods of using anti-SIRP? mAbs as therapeutics for the prevention and treatment of solid and hematological cancers. Also provided are amino acid sequences of exemplary anti-SIRP? monoclonal antibodies.

Abstract: Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, which include but are not limited to proteasome inhibitors, immunomodulatory agents, Bruton's tyrosine kinase (BTK) inhibitors, BCMA-targeting agents, CAR-T cells, anthracyclines, platinums, taxols, cyclophosphamides, topoisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, alkylating agents, and demethylating agents.

Abstract: Provided are compositions and methods for treating cancer by administering antiCD47 mAbs and anti-CD47 fusion proteins with distinct functional profiles or chimeric antigen receptor (CAR)-bearing immune effector cells in combination with analogs of interleukin proteins.

Abstract: Anti-SIRP? monoclonal antibodies (anti-SIRP? mAbs), including multispecific SIRP? antibodies, are provided with distinct functional profiles as are related compositions and methods of using anti-SIRP? mAbs as therapeutics for the prevention and treatment of solid and hematological cancers. Also provided are amino acid sequences of exemplary anti-SIRP? monoclonal antibodies.

Abstract: Anti-SIRP? monoclonal antibodies (anti-SIRP? mAbs), including multispecific SIRP? antibodies, are provided with distinct functional profiles as are related compositions and methods of using anti-SIRP? mAbs as therapeutics for the prevention and treatment of solid and hematological cancers. Also provided are amino acid sequences of exemplary anti-SIRP? monoclonal antibodies.

Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of isolated monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human hematologic malignancies. The invention further relates to binding assays, which utilize the isolated monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.